MetLife Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.17M | Sell |
57,027
-2,680
| -4% | -$337K | 0.04% | 427 |
|
|
2025
Q1 | $6.6M | Sell |
59,707
-1,735
| -3% | -$192K | 0.04% | 488 |
|
|
2024
Q4 | $8.39M | Buy |
61,442
+4,735
| +8% | +$646K | 0.05% | 320 |
|
|
2024
Q3 | $6.53M | Sell |
56,707
-895
| -2% | -$103K | 0.04% | 397 |
|
|
2024
Q2 | $7.93M | Sell |
57,602
-1,002
| -2% | -$138K | 0.05% | 302 |
|
|
2024
Q1 | $8.08M | Sell |
58,604
-744
| -1% | -$103K | 0.05% | 290 |
|
|
2023
Q4 | $7.82M | Sell |
59,348
-620
| -1% | -$81.7K | 0.06% | 285 |
|
|
2023
Q3 | $6.75M | Sell |
59,968
-2,512
| -4% | -$283K | 0.05% | 303 |
|
|
2023
Q2 | $5.89M | Sell |
62,480
-552
| -0.9% | -$52.1K | 0.04% | 366 |
|
|
2023
Q1 | $6.38M | Sell |
63,032
-1,238
| -2% | -$125K | 0.05% | 334 |
|
|
2022
Q4 | $7.68M | Sell |
64,270
-1,065
| -2% | -$127K | 0.06% | 273 |
|
|
2022
Q3 | $6.94M | Sell |
65,335
-683
| -1% | -$72.5K | 0.06% | 279 |
|
|
2022
Q2 | $6.44M | Buy |
66,018
+509
| +0.8% | +$49.6K | 0.05% | 311 |
|
|
2022
Q1 | $6.14M | Buy |
65,509
+19,535
| +42% | +$1.83M | 0.04% | 401 |
|
|
2021
Q4 | $3.92M | Buy |
45,974
+505
| +1% | +$43K | 0.03% | 527 |
|
|
2021
Q3 | $4.36M | Sell |
45,469
-1,773
| -4% | -$170K | 0.04% | 441 |
|
|
2021
Q2 | $4.6M | Sell |
47,242
-1,284
| -3% | -$125K | 0.04% | 433 |
|
|
2021
Q1 | $4.72M | Buy |
+48,526
| New | +$4.72M | 0.04% | 422 |
|
|
2019
Q2 | – | Sell |
-123
| Closed | -$10.8K | – | 2542 |
|
|
2019
Q1 | $10.8K | Buy |
123
+1
| +0.8% | +$88 | ﹤0.01% | 2389 |
|
|
2018
Q4 | $8.71K | Sell |
122
-1
| -0.8% | -$71 | ﹤0.01% | 2394 |
|
|
2018
Q3 | $15.1K | Buy |
+123
| New | +$15.1K | ﹤0.01% | 2400 |
|